Heart Failure Program
Heart Failure
Pre-clinicalActive
Key Facts
About Sequantrix
Sequantrix is a Munich-based biotech startup pioneering an AI-driven approach to treat fibrosis and chronic organ diseases. The company has built a proprietary platform combining one of the world's largest human multi-modal single-cell datasets with advanced organoid assays and animal models to discover and validate novel targets. Its initial focus is on high-mortality, high-unmet-need areas including chronic kidney disease, heart failure, and myelofibrosis, with ambitions to both develop its own pipeline and partner with pharmaceutical companies. As a young, private company, it is positioned in the pre-clinical discovery and validation stage.
View full company profileTherapeutic Areas
Other Heart Failure Drugs
| Drug | Company | Phase |
|---|---|---|
| Cardiac Cell Therapy Program | StemCardia | Pre-clinical |
| NTP42 | ATXA Therapeutics | Preclinical |
| Heart Failure Trial | Clinical Investigation Specialists | Not Specified |
| INPEFA (sotagliflozin) | Lexicon Pharmaceuticals | Approved |
| MyCardia™ | Avery Therapeutics | Pre-clinical |
| Cardiac Assist Device | Second Heart Assist | Pre-clinical |
| Isosorbide Dinitrate/Hydralazine HCl Tablets | i3 Pharmaceuticals | Approved |
| TLT-101 | TikkunLev Therapeutics | Pre-clinical |
| Undisclosed Heart Regeneration Program | Animatus Biosciences | Pre-clinical |
| AFteR Registry | Occlutech | N/A (Registry) |
| biotx.ai Target Discovery Collaboration | HeartBeat.bio | Pre-clinical |
| Surlorian | RyCarma Therapeutics | Phase 2 |